Phenominer Database Results (207 results)

 

How to display a graph
Strain Phenotype Conditions Study Experiment Name Sex Age # of Animals Formula Value Units SEM SD Method Method Duration Post Insult Type Post Insult Time Value Post Insult Time Unit Clinical Measurement Notes Record ID Study ID
SS.ZUC-Leprfa-/-/Slc inguinal fat pad weight to tibia length ratio bilateral ovariectomy (for 42 days) then 17 beta-estradiol (0.5 mg) (for 35 days) Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23. inguinal fat pad mass female 91 days 7 155.0 mg/mm 14.0 37.04 post excision weight measurement 0.0 ovariectomy 42 days sf/tl 101706 2622
SS.ZUC-Leprfa-/-/Slc retroperitoneal fat pad weight to tibia length ratio control condition Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. retroperitoneal fat pad mass male 91 days 7 399.11 mg/mm 19.55 51.72 post excision weight measurement 0.0 0 rf/tl 101773 2641
SS.ZUC-Leprfa-/-/Slc inguinal fat pad weight to tibia length ratio control condition Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. inguinal fat pad mass male 91 days 7 1105.49 mg/mm 59.28 156.84 post excision weight measurement 0.0 0 if/tl 101781 2641
SS.ZUC-Leprfa-/-/Slc heart ventricle septal wall thickness everolimus (0.83 mg/kg/d) (for 28 days) Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. heart left ventricle wall thickness male 91 days 12 0.16 cm 0.0 0.01 echocardiography 0.0 0 101786 2641
SS.ZUC-Leprfa-/-/Slc calculated heart left ventricle weight everolimus (0.83 mg/kg/d) (for 28 days) Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. heart left ventricle mass male 91 days 12 986.71 mg 25.23 87.4 echocardiography 0.0 0 101798 2641
SS.ZUC-Leprfa-/-/Slc tibia straight segment length atorvastatin (6 mg/kg/d) (for 28 days) Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4. tibia length male 91 days 13 34.58 mm 0.15 0.54 body measuring method 0.0 0 101972 2644
SS.ZUC-Leprfa-/-/Slc heart weight to tibia length ratio atorvastatin (20 mg/kg/d) (for 28 days) Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4. heart mass male 91 days 13 0.43 g/cm 0.01 0.04 post excision weight measurement 0.0 0 101976 2644
SS.ZUC-Leprfa-/-/Slc epididymal fat pad weight to tibia length ratio atorvastatin (6 mg/kg/d) (for 28 days) Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4. epididymal fat pad mass male 91 days 13 3.58 g/cm 0.12 0.42 post excision weight measurement 0.0 0 ef/tl 101984 2644
SS.ZUC-Leprfa-/-/Slc inguinal fat pad weight to tibia length ratio vehicle control condition (0.5 %) (for 28 days) Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4. inguinal fat pad mass male 91 days 13 1501.32 mg/mm 68.53 247.09 post excision weight measurement 0.0 0 if/tl 101989 2644
SS.ZUC-Leprfa-/-/Slc heart left ventricle end-diastolic diameter atorvastatin (6 mg/kg/d) (for 28 days) Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4. heart left ventricle end-diastolic diameter male 91 days 13 8.56 mm 0.08 0.29 echocardiography 0.0 0 101996 2644
SS.ZUC-Leprfa-/-/Slc heart weight to tibia length ratio everolimus (0.83 mg/kg/d) (for 28 days) Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. heart mass male 91 days 12 0.34 g/cm 0.0 0.0 post excision weight measurement 0.0 0 101758 2641
SS.ZUC-Leprfa-/-/Slc pancreas weight to tibia length everolimus (0.83 mg/kg/d) (for 28 days) Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. pancreas mass male 91 days 12 29.85 mg/mm 1.97 6.82 post excision weight measurement 0.0 0 p/tl 101836 2641
SS.ZUC-Leprfa-/-/Slc serum leptin level fasting (for 16 hours) Hattori T, et al., Nutr Diabetes. 2011 Jan 31;1:e1. doi: 10.1038/nutd.2010.1. blood leptin amount male 126 days 7 53.97 ng/ml 2.34 6.19 enzyme linked immunosorbent assay 0.0 0 101912 2642
SS.ZUC-Leprfa-/-/Slc serum high density lipoprotein cholesterol level fasting (for 16 hours) Hattori T, et al., Nutr Diabetes. 2011 Jan 31;1:e1. doi: 10.1038/nutd.2010.1. blood HDL cholesterol amount male 126 days 7 50.14 mg/dl 2.3 6.09 serum high-density lipoprotein-cholesterol measurement test 0.0 0 101924 2642
SS.ZUC-Leprfa-/-/Slc body weight bilateral ovariectomy (for 42 days) then 17 beta-estradiol (0.5 mg) (for 35 days) Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23. body mass female 91 days 7 339.0 g 13.0 34.39 body weighing method 0.0 ovariectomy 42 days 101664 2622
SS.ZUC-Leprfa-/-/Slc heart left ventricle fractional shortening bilateral ovariectomy (for 42 days) then 17 beta-estradiol (0.5 mg) (for 35 days) Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23. heart left ventricle end-diastolic diameter female 91 days 7 61.3 % 2.7 7.14 echocardiography 0.0 ovariectomy 42 days 101722 2622
SS.ZUC-Leprfa-/-/Slc heart left ventricle relative wall thickness bilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days) Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23. heart left ventricle wall thickness female 91 days 8 57.0 % 2.0 5.66 echocardiography 0.0 ovariectomy 42 days 101729 2622
SS.ZUC-Leprfa-/-/Slc left ventricular end-diastolic blood pressure bilateral ovariectomy (for 42 days) then 17 beta-estradiol (0.5 mg) (for 35 days) Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23. heart left ventricular blood pressure trait female 91 days 7 5.91 mmHg 0.18 0.48 vascular transducer tipped catheter 0.0 ovariectomy 42 days 101746 2622
SS.ZUC-Leprfa-/-/Slc serum low density lipoprotein cholesterol level atorvastatin (20 mg/kg/d) (for 28 days) Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4. blood LDL cholesterol amount male 91 days 7 57.25 mg/dl 13.15 34.79 serum low-density lipoprotein-cholesterol measurement test 0.0 0 101946 2644
SS.ZUC-Leprfa-/-/Slc serum high density lipoprotein cholesterol level atorvastatin (6 mg/kg/d) (for 28 days) Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4. blood HDL cholesterol amount male 91 days 7 94.83 mg/dl 6.35 16.8 serum high-density lipoprotein-cholesterol measurement test 0.0 0 101948 2644
SS.ZUC-Leprfa-/-/Slc serum high density lipoprotein cholesterol level atorvastatin (20 mg/kg/d) (for 28 days) Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4. blood HDL cholesterol amount male 91 days 7 99.71 mg/dl 5.83 15.42 serum high-density lipoprotein-cholesterol measurement test 0.0 0 101949 2644
SS.ZUC-Leprfa-/-/Slc serum free fatty acids level atorvastatin (6 mg/kg/d) (for 28 days) Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4. blood free fatty acid amount male 91 days 7 0.61 mmol/l 0.05 0.13 serum free fatty acid analysis 0.0 0 101954 2644
SS.ZUC-Leprfa-/-/Slc serum glucose level atorvastatin (20 mg/kg/d) (for 28 days) Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4. blood glucose amount male 91 days 7 154.33 mg/dl 15.15 40.08 serum glucose analysis 0.0 0 101958 2644
SS.ZUC-Leprfa-/-/Slc serum insulin level atorvastatin (20 mg/kg/d) (for 28 days) Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4. blood insulin amount male 91 days 7 0.0 mg/dl 0.0 0.0 serum insulin analysis 0.0 0 101961 2644
SS.ZUC-Leprfa-/-/Slc time constant of left ventricular pressure decay vehicle control condition (0.5 %) (for 28 days) Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4. heart left ventricular blood pressure trait male 91 days 13 33.52 ms 1.09 3.93 echocardiography 0.0 0 102019 2644
SS.ZUC-Leprfa-/-/Slc heart left ventricular end-diastolic blood pressure to heart left ventricular end-diastolic diameter ratio vehicle control condition (0.5 %) (for 28 days) Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4. heart left ventricular blood pressure trait male 91 days 13 2.1 mmHg/mm 0.13 0.47 vascular transducer tipped catheter 0.0 0 102025 2644
SS.ZUC-Leprfa-/-/Slc urine total protein level control condition Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. total urine protein amount male 91 days 7 15.51 mg/ml 1.69 4.46 urine protein analysis 0.0 0 101871 2641
SS.ZUC-Leprfa-/-/Slc body weight control condition Hattori T, et al., Nutr Diabetes. 2011 Jan 31;1:e1. doi: 10.1038/nutd.2010.1. body mass male 126 days 7 536.92 g 6.98 18.47 body weighing method 0.0 0 101886 2642
SS.ZUC-Leprfa-/-/Slc urine total protein level everolimus (0.83 mg/kg/d) (for 28 days) Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. total urine protein amount male 91 days 12 13.37 mg/ml 0.97 3.35 urine protein analysis 0.0 0 101872 2641
SS.ZUC-Leprfa-/-/Slc creatinine clearance to body weight ratio everolimus (0.83 mg/kg/d) (for 28 days) Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. glomerular filtration trait male 91 days 12 0.17 ml/min/100g 0.02 0.07 serum creatinine analysis 0.0 0 101880 2641
SS.ZUC-Leprfa-/-/Slc E wave deceleration time atorvastatin (20 mg/kg/d) (for 28 days) Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4. blood flow trait male 91 days 13 43.5 ms 1.57 5.66 echocardiography 0.0 0 102015 2644
SS.ZUC-Leprfa-/-/Slc time constant of left ventricular pressure decay atorvastatin (20 mg/kg/d) (for 28 days) Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4. heart left ventricular blood pressure trait male 91 days 13 22.53 ms 0.89 3.21 echocardiography 0.0 0 102021 2644
SS.ZUC-Leprfa-/-/Slc serum low density lipoprotein cholesterol level fasting (for 16 hours) Hattori T, et al., Nutr Diabetes. 2011 Jan 31;1:e1. doi: 10.1038/nutd.2010.1. blood LDL cholesterol amount male 126 days 7 73.85 mg/dl 7.15 18.92 serum low-density lipoprotein-cholesterol measurement test 0.0 0 101922 2642
SS.ZUC-Leprfa-/-/Slc retroperitoneal fat pad weight to tibia length ratio everolimus (0.83 mg/kg/d) (for 28 days) Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. retroperitoneal fat pad mass male 91 days 12 334.74 mg/mm 9.21 31.9 post excision weight measurement 0.0 0 rf/tl 101774 2641
SS.ZUC-Leprfa-/-/Slc inguinal fat pad weight to tibia length ratio atorvastatin (6 mg/kg/d) (for 28 days) Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4. inguinal fat pad mass male 91 days 13 1448.07 mg/mm 60.58 218.42 post excision weight measurement 0.0 0 if/tl 101990 2644
SS.ZUC-Leprfa-/-/Slc heart left ventricle weight to tibia length ratio atorvastatin (6 mg/kg/d) (for 28 days) Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4. heart left ventricle mass male 91 days 13 0.3 g/cm 0.01 0.03 post excision weight measurement 0.0 0 lv/tl 101978 2644
SS.ZUC-Leprfa-/-/Slc mesenteric fat pad weight to tibia length ratio atorvastatin (20 mg/kg/d) (for 28 days) Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4. mesenteric fat pad mass male 91 days 13 348.17 mg/mm 9.57 34.51 post excision weight measurement 0.0 0 mf/tl, mesenteric fat pad weight to tibia length ratio 101988 2644
SS.ZUC-Leprfa-/-/Slc tibia straight segment length bilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days) Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23. tibia length female 91 days 8 32.5 mm 0.9 2.55 body length measuring method 0.0 ovariectomy 42 days 101667 2622
SS.ZUC-Leprfa-/-/Slc tibia straight segment length bilateral ovariectomy (for 42 days) then 17 beta-estradiol (0.5 mg) (for 35 days) Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23. tibia length female 91 days 7 31.8 mm 0.6 1.59 body length measuring method 0.0 ovariectomy 42 days 101668 2622
SS.ZUC-Leprfa-/-/Slc systolic blood pressure bilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days) Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23. arterial blood pressure trait female 91 days 8 undefined 221.0 mmHg 5.0 14.14 tail cuff plethysmography 0.0 ovariectomy 42 days 101671 2622
SS.ZUC-Leprfa-/-/Slc heart left ventricle posterior wall thickness bilateral ovariectomy (for 42 days) then 17 beta-estradiol (0.5 mg) (for 35 days) Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23. heart left ventricle posterior wall thickness female 91 days 7 2.16 mm 0.06 0.16 echocardiography 0.0 ovariectomy 42 days 101714 2622
SS.ZUC-Leprfa-/-/Slc heart left ventricle end-diastolic diameter bilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days) Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23. heart left ventricle end-diastolic diameter female 91 days 8 7.2 mm 0.14 0.4 echocardiography 0.0 ovariectomy 42 days 101717 2622
SS.ZUC-Leprfa-/-/Slc heart left ventricle relative wall thickness bilateral ovariectomy (for 42 days) then 17 beta-estradiol (0.5 mg) (for 35 days) Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23. heart left ventricle wall thickness female 91 days 7 61.0 % 2.0 5.29 echocardiography 0.0 ovariectomy 42 days 101730 2622
SS.ZUC-Leprfa-/-/Slc E wave deceleration time bilateral ovariectomy (for 42 days) then 17 beta-estradiol (0.5 mg) (for 35 days) Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23. heart pumping trait female 91 days 7 59.9 ms 1.0 2.65 echocardiography 0.0 ovariectomy 42 days 101734 2622
SS.ZUC-Leprfa-/-/Slc heart isovolumetric relaxation time bilateral ovariectomy (for 42 days) then 17 beta-estradiol (0.5 mg) (for 35 days) Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23. heart muscle relaxation trait female 91 days 7 57.9 ms 4.2 11.11 echocardiography 0.0 ovariectomy 42 days 101738 2622
SS.ZUC-Leprfa-/-/Slc time constant of left ventricular pressure decay bilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days) Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23. heart left ventricular blood pressure trait female 91 days 8 47.3 ms 1.5 4.24 echocardiography 0.0 ovariectomy 42 days 101749 2622
SS.ZUC-Leprfa-/-/Slc heart left ventricular end-diastolic blood pressure to heart left ventricular end-diastolic diameter ratio bilateral ovariectomy (for 42 days) then 17 beta-estradiol (0.5 mg) (for 35 days) Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23. heart left ventricular blood pressure trait female 91 days 7 0.81 mmHg/mm 0.03 0.08 echocardiography 0.0 ovariectomy 42 days 101754 2622
SS.ZUC-Leprfa-/-/Slc heart left ventricular end-diastolic blood pressure to heart left ventricular end-diastolic diameter ratio everolimus (0.83 mg/kg/d) (for 28 days) Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. heart left ventricular blood pressure trait male 91 days 9 0.65 mmHg/mm 0.05 0.15 echocardiography 0.0 0 lvedp/lvdd 101832 2641
SS.ZUC-Leprfa-/-/Slc serum glucose level fasting (for 16 hours) Hattori T, et al., Nutr Diabetes. 2011 Jan 31;1:e1. doi: 10.1038/nutd.2010.1. blood glucose amount male 126 days 7 136.33 mg/dl 5.27 13.94 serum glucose analysis 0.0 0 101914 2642
SS.ZUC-Leprfa-/-/Slc serum alanine aminotransferase activity level fasting (for 16 hours) Hattori T, et al., Nutr Diabetes. 2011 Jan 31;1:e1. doi: 10.1038/nutd.2010.1. blood alanine transaminase amount male 126 days 7 39.25 U/l 2.63 6.96 automated blood analysis 0.0 0 101930 2642
SS.ZUC-Leprfa-/-/Slc creatinine clearance to total kidney weight ratio control condition Hattori T, et al., Nutr Diabetes. 2011 Jan 31;1:e1. doi: 10.1038/nutd.2010.1. glomerular filtration trait male 126 days 7 0.2 ml/min/g 0.03 0.08 urine creatinine analysis 0.0 0 101938 2642
SS.ZUC-Leprfa-/-/Slc ejection fraction everolimus (0.83 mg/kg/d) (for 28 days) Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. cardiac output trait male 91 days 12 76.47 % 1.2 4.16 echocardiography 0.0 0 101812 2641
SS.ZUC-Leprfa-/-/Slc heart isovolumetric relaxation time control condition Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. heart muscle relaxation trait male 91 days 7 38.35 ms 1.84 4.87 echocardiography 0.0 0 101823 2641
SS.ZUC-Leprfa-/-/Slc blood total cholesterol level control condition Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. blood cholesterol amount male 91 days 7 329.25 mg/dl 52.32 138.43 blood cholesterol analysis 0.0 0 101839 2641
SS.ZUC-Leprfa-/-/Slc serum triglyceride level everolimus (0.83 mg/kg/d) (for 28 days) Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. blood triglyceride amount male 91 days 12 1251.33 mg/dl 276.6 958.17 serum triglyceride analysis 0.0 0 101852 2641
SS.ZUC-Leprfa-/-/Slc serum free fatty acids level control condition Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. blood free fatty acid amount male 91 days 7 30.61 mmol/l 8.11 21.46 serum free fatty acid analysis 0.0 0 **suspected wrong units in paper(mg/dl) 101855 2641
SS.ZUC-Leprfa-/-/Slc blood alanine aminotransferase activity level control condition Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. blood alanine transaminase amount male 91 days 7 33.75 U/l 3.75 9.92 automated blood analysis 0.0 0 101863 2641
SS.ZUC-Leprfa-/-/Slc creatinine clearance to body weight ratio control condition Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. glomerular filtration trait male 91 days 7 0.28 ml/min/100g 0.03 0.08 serum creatinine analysis 0.0 0 101879 2641
SS.ZUC-Leprfa-/-/Slc heart left ventricle weight to tibia length ratio control condition Hattori T, et al., Nutr Diabetes. 2011 Jan 31;1:e1. doi: 10.1038/nutd.2010.1. heart left ventricle mass male 126 days 7 0.33 g/cm 0.0 0.01 post excision weight measurement 0.0 0 lv/tl 101896 2642
SS.ZUC-Leprfa-/-/Slc liver weight to tibia length ratio control condition Hattori T, et al., Nutr Diabetes. 2011 Jan 31;1:e1. doi: 10.1038/nutd.2010.1. liver mass male 126 days 7 600.11 mg/mm 42.14 111.49 post excision weight measurement 0.0 0 liv/tl 101904 2642
SS.ZUC-Leprfa-/-/Slc serum total cholesterol level atorvastatin (6 mg/kg/d) (for 28 days) Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4. blood cholesterol amount male 91 days 7 218.0 mg/dl 26.0 68.79 serum total cholesterol measurement test 0.0 0 101942 2644
SS.ZUC-Leprfa-/-/Slc serum total cholesterol level atorvastatin (20 mg/kg/d) (for 28 days) Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4. blood cholesterol amount male 91 days 7 200.33 mg/dl 44.7 118.27 serum total cholesterol measurement test 0.0 0 101943 2644
SS.ZUC-Leprfa-/-/Slc serum triglyceride level atorvastatin (6 mg/kg/d) (for 28 days) Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4. blood triglyceride amount male 91 days 7 1190.0 mg/dl 324.22 857.81 serum triglyceride analysis 0.0 0 101951 2644
SS.ZUC-Leprfa-/-/Slc serum free fatty acids level vehicle control condition (0.5 %) (for 28 days) Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4. blood free fatty acid amount male 91 days 6 1.42 mmol/l 0.14 0.34 serum free fatty acid analysis 0.0 0 101953 2644
SS.ZUC-Leprfa-/-/Slc serum free fatty acids level atorvastatin (20 mg/kg/d) (for 28 days) Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4. blood free fatty acid amount male 91 days 7 0.59 mmol/l 0.03 0.08 serum free fatty acid analysis 0.0 0 101955 2644
SS.ZUC-Leprfa-/-/Slc serum glucose level vehicle control condition (0.5 %) (for 28 days) Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4. blood glucose amount male 91 days 6 149.4 mg/dl 12.36 30.28 serum glucose analysis 0.0 0 101956 2644
SS.ZUC-Leprfa-/-/Slc heart left ventricle end-diastolic diameter atorvastatin (20 mg/kg/d) (for 28 days) Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4. heart left ventricle end-diastolic diameter male 91 days 13 8.43 mm 0.11 0.4 echocardiography 0.0 0 101997 2644
SS.ZUC-Leprfa-/-/Slc heart posterior wall thickness atorvastatin (6 mg/kg/d) (for 28 days) Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4. heart left ventricle posterior wall thickness male 91 days 13 0.2 cm 0.0 0.01 echocardiography 0.0 0 101999 2644
SS.ZUC-Leprfa-/-/Slc heart posterior wall thickness atorvastatin (20 mg/kg/d) (for 28 days) Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4. heart left ventricle posterior wall thickness male 91 days 13 0.2 cm 0.01 0.02 echocardiography 0.0 0 102000 2644
SS.ZUC-Leprfa-/-/Slc heart left ventricle relative wall thickness atorvastatin (6 mg/kg/d) (for 28 days) Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4. heart left ventricle wall thickness male 91 days 13 46.0 % 1.0 3.61 echocardiography 0.0 0 102005 2644
SS.ZUC-Leprfa-/-/Slc heart isovolumetric relaxation time vehicle control condition (0.5 %) (for 28 days) Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4. heart muscle relaxation trait male 91 days 13 40.75 ms 2.42 8.73 echocardiography 0.0 0 102016 2644
SS.ZUC-Leprfa-/-/Slc time constant of left ventricular pressure decay atorvastatin (6 mg/kg/d) (for 28 days) Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4. heart left ventricular blood pressure trait male 91 days 13 25.89 ms 1.53 5.52 echocardiography 0.0 0 102020 2644
SS.ZUC-Leprfa-/-/Slc left ventricular end-diastolic blood pressure atorvastatin (6 mg/kg/d) (for 28 days) Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4. heart left ventricular blood pressure trait male 91 days 13 10.39 mmHg 2.03 7.32 vascular transducer tipped catheter 0.0 0 102023 2644
SS.ZUC-Leprfa-/-/Slc heart left ventricle fractional shortening everolimus (0.83 mg/kg/d) (for 28 days) Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. heart left ventricle end-diastolic diameter male 91 days 12 38.55 % 1.09 3.78 echocardiography 0.0 0 101808 2641
SS.ZUC-Leprfa-/-/Slc E wave deceleration time everolimus (0.83 mg/kg/d) (for 28 days) Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. blood flow trait male 91 days 12 35.82 ms 0.68 2.36 echocardiography 0.0 0 101820 2641
SS.ZUC-Leprfa-/-/Slc serum urea nitrogen level control condition Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. blood urea nitrogen amount male 91 days 7 23.17 mg/dl 0.28 0.74 serum urea nitrogen analysis 0.0 0 101867 2641
SS.ZUC-Leprfa-/-/Slc myocardial performance index bilateral ovariectomy (for 42 days) then 17 beta-estradiol (0.5 mg) (for 35 days) Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23. heart pumping trait female 91 days 7 0.99 null 0.03 0.08 echocardiography 0.0 ovariectomy 42 days 101742 2622
SS.ZUC-Leprfa-/-/Slc serum aspartate aminotransferase activity level fasting (for 16 hours) Hattori T, et al., Nutr Diabetes. 2011 Jan 31;1:e1. doi: 10.1038/nutd.2010.1. blood aspartate transaminase amount male 126 days 7 67.33 U/l 4.67 12.36 automated blood analysis 0.0 0 101928 2642
SS.ZUC-Leprfa-/-/Slc heart left ventricle end-diastolic diameter vehicle control condition (0.5 %) (for 28 days) Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4. heart left ventricle end-diastolic diameter male 91 days 13 8.27 mm 0.13 0.47 echocardiography 0.0 0 101995 2644
SS.ZUC-Leprfa-/-/Slc single kidney weight to tibia length ratio control condition Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. kidney mass male 91 days 7 33.51 g/cm 0.99 2.62 post excision weight measurement 0.0 0 101769 2641
SS.ZUC-Leprfa-/-/Slc heart left ventricle posterior wall thickness control condition Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. heart left ventricle posterior wall thickness male 91 days 7 2.16 mm 0.09 0.24 echocardiography 0.0 0 101793 2641
SS.ZUC-Leprfa-/-/Slc calculated heart left ventricle weight control condition Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. heart left ventricle mass male 91 days 7 1286.0 mg 64.26 170.02 echocardiography 0.0 0 101797 2641
SS.ZUC-Leprfa-/-/Slc retroperitoneal fat pad weight to tibia length ratio bilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days) Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23. retroperitoneal fat pad mass female 91 days 8 482.0 mg/mm 18.0 50.91 post excision weight measurement 0.0 ovariectomy 42 days vf/tl 101701 2622
SS.ZUC-Leprfa-/-/Slc heart ventricle septal wall thickness bilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days) Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23. heart left ventricle wall thickness female 91 days 8 0.21 cm 0.0 0.01 echocardiography 0.0 ovariectomy 42 days 101709 2622
SS.ZUC-Leprfa-/-/Slc tibia straight segment length vehicle control condition (0.5 %) (for 28 days) Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4. tibia length male 91 days 13 34.62 mm 0.15 0.54 body measuring method 0.0 0 101971 2644
SS.ZUC-Leprfa-/-/Slc tibia straight segment length atorvastatin (20 mg/kg/d) (for 28 days) Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4. tibia length male 91 days 13 34.52 mm 0.21 0.76 body measuring method 0.0 0 101973 2644
SS.ZUC-Leprfa-/-/Slc heart weight to tibia length ratio atorvastatin (6 mg/kg/d) (for 28 days) Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4. heart mass male 91 days 13 0.42 g/cm 0.01 0.04 post excision weight measurement 0.0 0 101975 2644
SS.ZUC-Leprfa-/-/Slc heart left ventricle weight to tibia length ratio atorvastatin (20 mg/kg/d) (for 28 days) Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4. heart left ventricle mass male 91 days 13 0.31 g/cm 0.01 0.03 post excision weight measurement 0.0 0 lv/tl 101979 2644
SS.ZUC-Leprfa-/-/Slc heart ventricle septal wall thickness atorvastatin (20 mg/kg/d) (for 28 days) Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4. heart left ventricle wall thickness male 91 days 13 0.2 cm 0.0 0.01 echocardiography 0.0 0 101994 2644
SS.ZUC-Leprfa-/-/Slc liver weight to tibia length ratio everolimus (0.83 mg/kg/d) (for 28 days) Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. liver mass male 91 days 12 568.94 mg/mm 19.5 67.55 post excision weight measurement 0.0 0 liv/tl 101766 2641
SS.ZUC-Leprfa-/-/Slc heart left ventricle relative wall thickness control condition Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. heart left ventricle wall thickness male 91 days 7 57.0 % 4.0 10.58 echocardiography 0.0 0 101803 2641
SS.ZUC-Leprfa-/-/Slc heart left ventricular end-diastolic blood pressure to heart left ventricular end-diastolic diameter ratio control condition Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. heart left ventricular blood pressure trait male 91 days 3 1.08 mmHg/mm 0.11 0.19 echocardiography 0.0 0 lvedp/lvdd 101831 2641
SS.ZUC-Leprfa-/-/Slc serum triglyceride level fasting (for 16 hours) Hattori T, et al., Nutr Diabetes. 2011 Jan 31;1:e1. doi: 10.1038/nutd.2010.1. blood triglyceride amount male 126 days 7 1559.93 mg/dl 353.89 936.3 serum triglyceride analysis 0.0 0 101918 2642
SS.ZUC-Leprfa-/-/Slc serum total cholesterol level fasting (for 16 hours) Hattori T, et al., Nutr Diabetes. 2011 Jan 31;1:e1. doi: 10.1038/nutd.2010.1. blood cholesterol amount male 126 days 7 371.14 mg/dl 39.21 103.74 serum total cholesterol measurement test 0.0 0 101920 2642
SS.ZUC-Leprfa-/-/Slc serum low density lipoprotein cholesterol to high density lipoprotein cholesterol ratio fasting (for 16 hours) Hattori T, et al., Nutr Diabetes. 2011 Jan 31;1:e1. doi: 10.1038/nutd.2010.1. blood cholesterol amount male 126 days 6 1.59 null 0.15 0.37 serum high-density lipoprotein-cholesterol measurement test 0.0 0 ldl/hdl 101926 2642
SS.ZUC-Leprfa-/-/Slc serum creatinine level fasting (for 16 hours) Hattori T, et al., Nutr Diabetes. 2011 Jan 31;1:e1. doi: 10.1038/nutd.2010.1. blood creatinine amount male 126 days 7 1.09 mg/dl 0.19 0.5 serum creatinine analysis 0.0 0 101934 2642
SS.ZUC-Leprfa-/-/Slc urine protein level control condition Hattori T, et al., Nutr Diabetes. 2011 Jan 31;1:e1. doi: 10.1038/nutd.2010.1. total urine protein amount male 126 days 7 735.52 mg/d 93.97 248.62 urine protein analysis 0.0 0 101936 2642
SS.ZUC-Leprfa-/-/Slc creatinine clearance to body weight ratio control condition Hattori T, et al., Nutr Diabetes. 2011 Jan 31;1:e1. doi: 10.1038/nutd.2010.1. glomerular filtration trait male 126 days 7 0.18 ml/min/100g 0.02 0.05 urine creatinine analysis 0.0 0 101940 2642
SS.ZUC-Leprfa-/-/Slc heart left ventricle end-diastolic diameter bilateral ovariectomy (for 42 days) then 17 beta-estradiol (0.5 mg) (for 35 days) Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23. heart left ventricle end-diastolic diameter female 91 days 7 7.1 mm 0.12 0.32 echocardiography 0.0 ovariectomy 42 days 101718 2622
SS.ZUC-Leprfa-/-/Slc E wave deceleration time bilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days) Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23. heart pumping trait female 91 days 8 56.9 ms 1.8 5.09 echocardiography 0.0 ovariectomy 42 days 101733 2622
SS.ZUC-Leprfa-/-/Slc heart left ventricle fractional shortening control condition Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. heart left ventricle end-diastolic diameter male 91 days 7 44.43 % 1.71 4.52 echocardiography 0.0 0 101807 2641
SS.ZUC-Leprfa-/-/Slc E wave deceleration time control condition Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. blood flow trait male 91 days 7 43.45 ms 1.23 3.25 echocardiography 0.0 0 101819 2641
SS.ZUC-Leprfa-/-/Slc blood high density lipoprotein cholesterol level everolimus (0.83 mg/kg/d) (for 28 days) Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. blood HDL cholesterol amount male 91 days 12 67.83 mg/dl 15.23 52.76 blood cholesterol analysis 0.0 0 101844 2641
SS.ZUC-Leprfa-/-/Slc serum creatinine level everolimus (0.83 mg/kg/d) (for 28 days) Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. blood creatinine amount male 91 days 12 0.37 mg/dl 0.03 0.1 serum creatinine analysis 0.0 0 101876 2641
SS.ZUC-Leprfa-/-/Slc tibia straight segment length control condition Hattori T, et al., Nutr Diabetes. 2011 Jan 31;1:e1. doi: 10.1038/nutd.2010.1. tibia length male 126 days 7 36.47 mm 0.12 0.32 body measuring method 0.0 0 101888 2642
SS.ZUC-Leprfa-/-/Slc heart rate control condition Hattori T, et al., Nutr Diabetes. 2011 Jan 31;1:e1. doi: 10.1038/nutd.2010.1. heart pumping trait male 126 days 7 400.73 beats/min 15.4 40.74 tail cuff plethysmography 0.0 0 101892 2642
SS.ZUC-Leprfa-/-/Slc both kidneys wet weight to tibia length ratio control condition Hattori T, et al., Nutr Diabetes. 2011 Jan 31;1:e1. doi: 10.1038/nutd.2010.1. kidney mass male 126 days 7 1.29 g/cm 0.04 0.1 post excision weight measurement 0.0 0 101902 2642
SS.ZUC-Leprfa-/-/Slc serum high density lipoprotein cholesterol level vehicle control condition (0.5 %) (for 28 days) Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4. blood HDL cholesterol amount male 91 days 6 97.25 mg/dl 15.33 37.55 serum high-density lipoprotein-cholesterol measurement test 0.0 0 101947 2644
SS.ZUC-Leprfa-/-/Slc serum triglyceride level vehicle control condition (0.5 %) (for 28 days) Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4. blood triglyceride amount male 91 days 6 2196.13 mg/dl 204.52 500.97 serum triglyceride analysis 0.0 0 101950 2644
SS.ZUC-Leprfa-/-/Slc ejection fraction vehicle control condition (0.5 %) (for 28 days) Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4. cardiac output trait male 91 days 13 82.5 % 1.94 6.99 echocardiography 0.0 0 102010 2644
SS.ZUC-Leprfa-/-/Slc ejection fraction atorvastatin (6 mg/kg/d) (for 28 days) Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4. cardiac output trait male 91 days 13 79.33 % 1.21 4.36 echocardiography 0.0 0 102011 2644
SS.ZUC-Leprfa-/-/Slc serum free fatty acids level everolimus (0.83 mg/kg/d) (for 28 days) Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. blood free fatty acid amount male 91 days 12 19.47 mmol/l 1.16 4.02 serum free fatty acid analysis 0.0 0 **suspected wrong units in paper(mg/dl) 101856 2641
SS.ZUC-Leprfa-/-/Slc blood aspartate aminotransferase activity level control condition Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. blood aspartate transaminase amount male 91 days 7 45.0 U/l 3.53 9.34 automated blood analysis 0.0 0 101859 2641
SS.ZUC-Leprfa-/-/Slc creatinine clearance to total kidney weight ratio control condition Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. glomerular filtration trait male 91 days 7 0.4 ml/min/g 0.03 0.08 serum creatinine analysis 0.0 0 101883 2641
SS.ZUC-Leprfa-/-/Slc E wave deceleration time vehicle control condition (0.5 %) (for 28 days) Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4. blood flow trait male 91 days 13 53.05 ms 1.48 5.34 echocardiography 0.0 0 102013 2644
SS.ZUC-Leprfa-/-/Slc heart isovolumetric relaxation time atorvastatin (20 mg/kg/d) (for 28 days) Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4. heart muscle relaxation trait male 91 days 13 29.2 ms 1.79 6.45 echocardiography 0.0 0 102018 2644
SS.ZUC-Leprfa-/-/Slc heart left ventricular end-diastolic blood pressure to heart left ventricular end-diastolic diameter ratio atorvastatin (20 mg/kg/d) (for 28 days) Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4. heart left ventricular blood pressure trait male 91 days 13 1.05 mmHg/mm 0.24 0.87 vascular transducer tipped catheter 0.0 0 102027 2644
SS.ZUC-Leprfa-/-/Slc mesenteric fat pad weight to tibia length ratio atorvastatin (6 mg/kg/d) (for 28 days) Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4. mesenteric fat pad mass male 91 days 13 371.46 mg/mm 9.6 34.61 post excision weight measurement 0.0 0 mf/tl 101987 2644
SS.ZUC-Leprfa-/-/Slc inguinal fat pad weight to tibia length ratio everolimus (0.83 mg/kg/d) (for 28 days) Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. inguinal fat pad mass male 91 days 12 765.81 mg/mm 23.86 82.65 post excision weight measurement 0.0 0 if/tl 101782 2641
SS.ZUC-Leprfa-/-/Slc heart left ventricle weight to tibia length ratio bilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days) Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23. heart left ventricle mass female 91 days 8 0.28 g/cm 0.01 0.02 post excision weight measurement 0.0 ovariectomy 42 days lv/tl 101697 2622
SS.ZUC-Leprfa-/-/Slc single kidney weight to tibia length ratio everolimus (0.83 mg/kg/d) (for 28 days) Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. kidney mass male 91 days 12 25.22 g/cm 0.65 2.26 post excision weight measurement 0.0 0 101770 2641
SS.ZUC-Leprfa-/-/Slc epididymal fat pad weight to tibia length ratio everolimus (0.83 mg/kg/d) (for 28 days) Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. epididymal fat pad mass male 91 days 12 2.43 g/cm 0.1 0.35 post excision weight measurement 0.0 0 ef/tl 101778 2641
SS.ZUC-Leprfa-/-/Slc heart ventricle septal wall thickness control condition Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. heart left ventricle wall thickness male 91 days 7 0.21 cm 0.01 0.03 echocardiography 0.0 0 101785 2641
SS.ZUC-Leprfa-/-/Slc heart left ventricle posterior wall thickness everolimus (0.83 mg/kg/d) (for 28 days) Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. heart left ventricle posterior wall thickness male 91 days 12 1.68 mm 0.05 0.17 echocardiography 0.0 0 101794 2641
SS.ZUC-Leprfa-/-/Slc retroperitoneal fat pad weight to tibia length ratio bilateral ovariectomy (for 42 days) then 17 beta-estradiol (0.5 mg) (for 35 days) Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23. retroperitoneal fat pad mass female 91 days 7 377.0 mg/mm 33.0 87.31 post excision weight measurement 0.0 ovariectomy 42 days 101702 2622
SS.ZUC-Leprfa-/-/Slc heart weight to tibia length ratio vehicle control condition (0.5 %) (for 28 days) Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4. heart mass male 91 days 13 0.43 g/cm 0.01 0.04 post excision weight measurement 0.0 0 101974 2644
SS.ZUC-Leprfa-/-/Slc heart left ventricle weight to tibia length ratio vehicle control condition (0.5 %) (for 28 days) Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4. heart left ventricle mass male 91 days 13 0.31 g/cm 0.01 0.03 post excision weight measurement 0.0 0 lv/tl 101977 2644
SS.ZUC-Leprfa-/-/Slc retroperitoneal fat pad weight to tibia length ratio vehicle control condition (0.5 %) (for 28 days) Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4. retroperitoneal fat pad mass male 91 days 13 429.56 mg/mm 13.64 49.18 post excision weight measurement 0.0 0 rf/tl 101980 2644
SS.ZUC-Leprfa-/-/Slc retroperitoneal fat pad weight to tibia length ratio atorvastatin (6 mg/kg/d) (for 28 days) Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4. retroperitoneal fat pad mass male 91 days 13 415.13 mg/mm 12.15 43.81 post excision weight measurement 0.0 0 rf/tl 101981 2644
SS.ZUC-Leprfa-/-/Slc epididymal fat pad weight to tibia length ratio vehicle control condition (0.5 %) (for 28 days) Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4. epididymal fat pad mass male 91 days 13 3.55 g/cm 0.1 0.35 post excision weight measurement 0.0 0 ef/tl 101983 2644
SS.ZUC-Leprfa-/-/Slc heart weight to tibia length ratio bilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days) Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23. heart mass female 91 days 8 0.35 g/cm 0.0 0.0 post excision weight measurement 0.0 ovariectomy 42 days 101693 2622
SS.ZUC-Leprfa-/-/Slc heart left ventricle relative wall thickness everolimus (0.83 mg/kg/d) (for 28 days) Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. heart left ventricle wall thickness male 91 days 12 41.0 % 1.0 3.46 echocardiography 0.0 0 101804 2641
SS.ZUC-Leprfa-/-/Slc serum insulin level fasting (for 16 hours) Hattori T, et al., Nutr Diabetes. 2011 Jan 31;1:e1. doi: 10.1038/nutd.2010.1. blood insulin amount male 126 days 7 0.0 mg/dl 0.0 0.0 enzyme linked immunosorbent assay 0.0 0 101916 2642
SS.ZUC-Leprfa-/-/Slc serum urea nitrogen level fasting (for 16 hours) Hattori T, et al., Nutr Diabetes. 2011 Jan 31;1:e1. doi: 10.1038/nutd.2010.1. blood urea nitrogen amount male 126 days 7 76.21 mg/dl 13.56 35.88 serum urea nitrogen analysis 0.0 0 101932 2642
SS.ZUC-Leprfa-/-/Slc body weight bilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days) Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23. body mass female 91 days 8 393.0 g 6.0 16.97 body weighing method 0.0 ovariectomy 42 days 101663 2622
SS.ZUC-Leprfa-/-/Slc systolic blood pressure bilateral ovariectomy (for 42 days) then 17 beta-estradiol (0.5 mg) (for 35 days) Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23. arterial blood pressure trait female 91 days 7 undefined 202.0 mmHg 6.0 15.87 tail cuff plethysmography 0.0 ovariectomy 42 days 101672 2622
SS.ZUC-Leprfa-/-/Slc heart rate bilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days) Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23. heart pumping trait female 91 days 8 339.0 beats/min 11.0 31.11 tail cuff plethysmography 0.0 ovariectomy 42 days 101675 2622
SS.ZUC-Leprfa-/-/Slc heart rate bilateral ovariectomy (for 42 days) then 17 beta-estradiol (0.5 mg) (for 35 days) Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23. heart pumping trait female 91 days 7 366.0 beats/min 8.0 21.17 tail cuff plethysmography 0.0 ovariectomy 42 days 101676 2622
SS.ZUC-Leprfa-/-/Slc heart left ventricle posterior wall thickness bilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days) Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23. heart left ventricle posterior wall thickness female 91 days 8 2.06 mm 0.04 0.11 echocardiography 0.0 ovariectomy 42 days 101713 2622
SS.ZUC-Leprfa-/-/Slc calculated heart left ventricle weight bilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days) Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23. heart left ventricle mass female 91 days 8 1114.0 mg 35.0 98.99 echocardiography 0.0 ovariectomy 42 days 101725 2622
SS.ZUC-Leprfa-/-/Slc myocardial performance index bilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days) Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23. heart pumping trait female 91 days 8 0.61 null 0.03 0.08 echocardiography 0.0 ovariectomy 42 days 101741 2622
SS.ZUC-Leprfa-/-/Slc heart left ventricular end-diastolic blood pressure to heart left ventricular end-diastolic diameter ratio bilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days) Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23. heart left ventricular blood pressure trait female 91 days 8 0.63 mmHg/mm 0.05 0.14 echocardiography 0.0 ovariectomy 42 days 101753 2622
SS.ZUC-Leprfa-/-/Slc serum low density lipoprotein cholesterol level vehicle control condition (0.5 %) (for 28 days) Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4. blood LDL cholesterol amount male 91 days 6 102.5 mg/dl 9.37 22.95 serum low-density lipoprotein-cholesterol measurement test 0.0 0 101944 2644
SS.ZUC-Leprfa-/-/Slc serum low density lipoprotein cholesterol level atorvastatin (6 mg/kg/d) (for 28 days) Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4. blood LDL cholesterol amount male 91 days 7 66.0 mg/dl 9.1 24.08 serum low-density lipoprotein-cholesterol measurement test 0.0 0 101945 2644
SS.ZUC-Leprfa-/-/Slc serum triglyceride level atorvastatin (20 mg/kg/d) (for 28 days) Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4. blood triglyceride amount male 91 days 7 980.67 mg/dl 302.75 801.0 serum triglyceride analysis 0.0 0 101952 2644
SS.ZUC-Leprfa-/-/Slc serum glucose level atorvastatin (6 mg/kg/d) (for 28 days) Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4. blood glucose amount male 91 days 7 143.0 mg/dl 14.78 39.1 serum glucose analysis 0.0 0 101957 2644
SS.ZUC-Leprfa-/-/Slc serum insulin level atorvastatin (6 mg/kg/d) (for 28 days) Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4. blood insulin amount male 91 days 7 0.0 mg/dl 0.0 0.0 serum insulin analysis 0.0 0 101960 2644
SS.ZUC-Leprfa-/-/Slc heart posterior wall thickness vehicle control condition (0.5 %) (for 28 days) Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4. heart left ventricle posterior wall thickness male 91 days 13 0.21 cm 0.01 0.02 echocardiography 0.0 0 101998 2644
SS.ZUC-Leprfa-/-/Slc heart left ventricle relative wall thickness vehicle control condition (0.5 %) (for 28 days) Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4. heart left ventricle wall thickness male 91 days 13 49.0 % 1.0 3.61 echocardiography 0.0 0 102004 2644
SS.ZUC-Leprfa-/-/Slc heart left ventricle relative wall thickness atorvastatin (20 mg/kg/d) (for 28 days) Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4. heart left ventricle wall thickness male 91 days 13 47.0 % 2.0 7.21 echocardiography 0.0 0 102006 2644
SS.ZUC-Leprfa-/-/Slc heart left ventricle fractional shortening vehicle control condition (0.5 %) (for 28 days) Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4. heart left ventricle end-diastolic diameter male 91 days 13 47.66 % 2.43 8.76 echocardiography 0.0 0 102007 2644
SS.ZUC-Leprfa-/-/Slc heart left ventricle fractional shortening atorvastatin (20 mg/kg/d) (for 28 days) Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4. heart left ventricle end-diastolic diameter male 91 days 13 44.28 % 1.6 5.77 echocardiography 0.0 0 102009 2644
SS.ZUC-Leprfa-/-/Slc ejection fraction atorvastatin (20 mg/kg/d) (for 28 days) Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4. cardiac output trait male 91 days 13 79.88 % 1.51 5.44 echocardiography 0.0 0 102012 2644
SS.ZUC-Leprfa-/-/Slc E wave deceleration time atorvastatin (6 mg/kg/d) (for 28 days) Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4. blood flow trait male 91 days 13 46.93 ms 1.06 3.82 echocardiography 0.0 0 102014 2644
SS.ZUC-Leprfa-/-/Slc heart isovolumetric relaxation time atorvastatin (6 mg/kg/d) (for 28 days) Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4. heart muscle relaxation trait male 91 days 13 32.78 ms 1.14 4.11 echocardiography 0.0 0 102017 2644
SS.ZUC-Leprfa-/-/Slc left ventricular end-diastolic blood pressure vehicle control condition (0.5 %) (for 28 days) Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4. heart left ventricular blood pressure trait male 91 days 13 17.65 mmHg 1.43 5.16 vascular transducer tipped catheter 0.0 0 102022 2644
SS.ZUC-Leprfa-/-/Slc ejection fraction control condition Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. cardiac output trait male 91 days 7 82.46 % 1.65 4.37 echocardiography 0.0 0 101811 2641
SS.ZUC-Leprfa-/-/Slc time constant of left ventricular pressure decay control condition Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. heart left ventricular blood pressure trait male 91 days 7 36.72 ms 1.45 3.84 echocardiography 0.0 0 101827 2641
SS.ZUC-Leprfa-/-/Slc time constant of left ventricular pressure decay everolimus (0.83 mg/kg/d) (for 28 days) Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. heart left ventricular blood pressure trait male 91 days 12 28.77 ms 1.73 5.99 echocardiography 0.0 0 101828 2641
SS.ZUC-Leprfa-/-/Slc blood low density lipoprotein cholesterol level control condition Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. blood LDL cholesterol amount male 91 days 7 44.25 mg/dl 2.4 6.35 blood cholesterol analysis 0.0 0 101847 2641
SS.ZUC-Leprfa-/-/Slc serum urea nitrogen level everolimus (0.83 mg/kg/d) (for 28 days) Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. blood urea nitrogen amount male 91 days 12 27.42 mg/dl 1.23 4.26 serum urea nitrogen analysis 0.0 0 101868 2641
SS.ZUC-Leprfa-/-/Slc creatinine clearance to total kidney weight ratio everolimus (0.83 mg/kg/d) (for 28 days) Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. glomerular filtration trait male 91 days 12 0.28 ml/min/g 0.04 0.14 serum creatinine analysis 0.0 0 101884 2641
SS.ZUC-Leprfa-/-/Slc retroperitoneal fat pad weight to tibia length ratio control condition Hattori T, et al., Nutr Diabetes. 2011 Jan 31;1:e1. doi: 10.1038/nutd.2010.1. retroperitoneal fat pad mass male 126 days 7 839.28 mg/mm 33.0 87.31 post excision weight measurement 0.0 0 rf/tl 101906 2642
SS.ZUC-Leprfa-/-/Slc inguinal fat pad weight to tibia length ratio control condition Hattori T, et al., Nutr Diabetes. 2011 Jan 31;1:e1. doi: 10.1038/nutd.2010.1. inguinal fat pad mass male 126 days 7 795.02 mg/mm 41.33 109.35 post excision weight measurement 0.0 0 if/tl 101908 2642
SS.ZUC-Leprfa-/-/Slc serum creatinine level control condition Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. blood creatinine amount male 91 days 7 0.34 mg/dl 0.04 0.11 serum creatinine analysis 0.0 0 101875 2641
SS.ZUC-Leprfa-/-/Slc heart left ventricle fractional shortening atorvastatin (6 mg/kg/d) (for 28 days) Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4. heart left ventricle end-diastolic diameter male 91 days 13 43.53 % 1.18 4.25 echocardiography 0.0 0 102008 2644
SS.ZUC-Leprfa-/-/Slc heart isovolumetric relaxation time everolimus (0.83 mg/kg/d) (for 28 days) Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. heart muscle relaxation trait male 91 days 12 34.39 ms 1.07 3.71 echocardiography 0.0 0 101824 2641
SS.ZUC-Leprfa-/-/Slc blood high density lipoprotein cholesterol level control condition Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. blood HDL cholesterol amount male 91 days 7 73.0 mg/dl 15.83 41.88 blood cholesterol analysis 0.0 0 101843 2641
SS.ZUC-Leprfa-/-/Slc serum triglyceride level control condition Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. blood triglyceride amount male 91 days 7 1885.5 mg/dl 325.31 860.69 serum triglyceride analysis 0.0 0 101851 2641
SS.ZUC-Leprfa-/-/Slc blood alanine aminotransferase activity level everolimus (0.83 mg/kg/d) (for 28 days) Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. blood alanine transaminase amount male 91 days 12 46.67 U/l 2.44 8.45 automated blood analysis 0.0 0 101864 2641
SS.ZUC-Leprfa-/-/Slc heart ventricle septal wall thickness atorvastatin (6 mg/kg/d) (for 28 days) Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4. heart left ventricle wall thickness male 91 days 13 0.2 cm 0.0 0.01 echocardiography 0.0 0 101993 2644
SS.ZUC-Leprfa-/-/Slc inguinal fat pad weight to tibia length ratio bilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days) Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23. inguinal fat pad mass female 91 days 8 209.0 mg/mm 12.0 33.94 post excision weight measurement 0.0 ovariectomy 42 days sf/tl 101705 2622
SS.ZUC-Leprfa-/-/Slc left ventricular end-diastolic blood pressure bilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days) Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23. heart left ventricular blood pressure trait female 91 days 8 4.43 mmHg 0.21 0.59 vascular transducer tipped catheter 0.0 ovariectomy 42 days 101745 2622
SS.ZUC-Leprfa-/-/Slc pancreas weight to tibia length control condition Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. pancreas mass male 91 days 7 28.68 mg/mm 1.66 4.39 post excision weight measurement 0.0 0 p/tl 101835 2641
SS.ZUC-Leprfa-/-/Slc heart left ventricle weight to tibia length ratio bilateral ovariectomy (for 42 days) then 17 beta-estradiol (0.5 mg) (for 35 days) Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23. heart left ventricle mass female 91 days 7 0.28 g/cm 0.01 0.02 post excision weight measurement 0.0 ovariectomy 42 days 101698 2622
SS.ZUC-Leprfa-/-/Slc heart ventricle septal wall thickness bilateral ovariectomy (for 42 days) then 17 beta-estradiol (0.5 mg) (for 35 days) Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23. heart left ventricle wall thickness female 91 days 7 0.21 cm 0.01 0.01 echocardiography 0.0 ovariectomy 42 days 101710 2622
SS.ZUC-Leprfa-/-/Slc heart left ventricle end-diastolic diameter control condition Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. heart left ventricle end-diastolic diameter male 91 days 7 7.58 mm 0.2 0.53 echocardiography 0.0 0 101789 2641
SS.ZUC-Leprfa-/-/Slc heart left ventricle end-diastolic diameter everolimus (0.83 mg/kg/d) (for 28 days) Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. heart left ventricle end-diastolic diameter male 91 days 12 8.05 mm 0.07 0.24 echocardiography 0.0 0 101790 2641
SS.ZUC-Leprfa-/-/Slc retroperitoneal fat pad weight to tibia length ratio atorvastatin (20 mg/kg/d) (for 28 days) Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4. retroperitoneal fat pad mass male 91 days 13 429.58 mg/mm 14.03 50.59 post excision weight measurement 0.0 0 rf/tl 101982 2644
SS.ZUC-Leprfa-/-/Slc epididymal fat pad weight to tibia length ratio atorvastatin (20 mg/kg/d) (for 28 days) Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4. epididymal fat pad mass male 91 days 13 3.62 g/cm 0.09 0.34 post excision weight measurement 0.0 0 ef/tl 101985 2644
SS.ZUC-Leprfa-/-/Slc mesenteric fat pad weight to tibia length ratio vehicle control condition (0.5 %) (for 28 days) Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4. mesenteric fat pad mass male 91 days 13 364.22 mg/mm 10.33 37.25 post excision weight measurement 0.0 0 mf/tl 101986 2644
SS.ZUC-Leprfa-/-/Slc inguinal fat pad weight to tibia length ratio atorvastatin (20 mg/kg/d) (for 28 days) Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4. inguinal fat pad mass male 91 days 13 1482.16 mg/mm 53.88 194.27 post excision weight measurement 0.0 0 if/tl 101991 2644
SS.ZUC-Leprfa-/-/Slc heart ventricle septal wall thickness vehicle control condition (0.5 %) (for 28 days) Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4. heart left ventricle wall thickness male 91 days 13 0.21 cm 0.0 0.01 echocardiography 0.0 0 101992 2644
SS.ZUC-Leprfa-/-/Slc heart weight to tibia length ratio bilateral ovariectomy (for 42 days) then 17 beta-estradiol (0.5 mg) (for 35 days) Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23. heart mass female 91 days 7 0.35 g/cm 0.0 0.0 post excision weight measurement 0.0 ovariectomy 42 days 101694 2622
SS.ZUC-Leprfa-/-/Slc heart weight to tibia length ratio control condition Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. heart mass male 91 days 7 0.43 g/cm 0.01 0.0 post excision weight measurement 0.0 0 101757 2641
SS.ZUC-Leprfa-/-/Slc heart left ventricle weight to tibia length ratio control condition Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. heart left ventricle mass male 91 days 7 0.32 g/cm 0.01 0.01 post excision weight measurement 0.0 0 lv/tl 101761 2641
SS.ZUC-Leprfa-/-/Slc liver weight to tibia length ratio control condition Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. liver mass male 91 days 7 612.89 mg/mm 31.39 83.05 post excision weight measurement 0.0 0 liv/tl 101765 2641
SS.ZUC-Leprfa-/-/Slc heart left ventricle fractional shortening bilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days) Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23. heart left ventricle end-diastolic diameter female 91 days 8 47.7 % 1.9 5.37 echocardiography 0.0 ovariectomy 42 days 101721 2622
SS.ZUC-Leprfa-/-/Slc calculated heart left ventricle weight bilateral ovariectomy (for 42 days) then 17 beta-estradiol (0.5 mg) (for 35 days) Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23. heart left ventricle mass female 91 days 7 1176.0 mg 46.0 121.7 echocardiography 0.0 ovariectomy 42 days 101726 2622
SS.ZUC-Leprfa-/-/Slc heart isovolumetric relaxation time bilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days) Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23. heart muscle relaxation trait female 91 days 8 43.1 ms 1.5 4.24 echocardiography 0.0 ovariectomy 42 days 101737 2622
SS.ZUC-Leprfa-/-/Slc time constant of left ventricular pressure decay bilateral ovariectomy (for 42 days) then 17 beta-estradiol (0.5 mg) (for 35 days) Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23. heart left ventricular blood pressure trait female 91 days 7 62.4 ms 3.3 8.73 echocardiography 0.0 ovariectomy 42 days 101750 2622
SS.ZUC-Leprfa-/-/Slc E/A wave ratio control condition Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. blood flow trait male 91 days 7 1.54 null 0.13 0.34 echocardiography 0.0 0 101815 2641
SS.ZUC-Leprfa-/-/Slc E/A wave ratio everolimus (0.83 mg/kg/d) (for 28 days) Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. blood flow trait male 91 days 12 1.91 null 0.07 0.24 echocardiography 0.0 0 e/a 101816 2641
SS.ZUC-Leprfa-/-/Slc blood aspartate aminotransferase activity level everolimus (0.83 mg/kg/d) (for 28 days) Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. blood aspartate transaminase amount male 91 days 12 65.6 U/l 7.65 26.5 automated blood analysis 0.0 0 101860 2641
SS.ZUC-Leprfa-/-/Slc systolic blood pressure control condition Hattori T, et al., Nutr Diabetes. 2011 Jan 31;1:e1. doi: 10.1038/nutd.2010.1. arterial blood pressure trait male 126 days 7 210.62 mmHg 2.54 6.72 tail cuff plethysmography 0.0 0 101890 2642
SS.ZUC-Leprfa-/-/Slc heart weight to tibia length ratio control condition Hattori T, et al., Nutr Diabetes. 2011 Jan 31;1:e1. doi: 10.1038/nutd.2010.1. heart mass male 126 days 7 0.42 g/cm 0.0 0.01 post excision weight measurement 0.0 0 101894 2642
SS.ZUC-Leprfa-/-/Slc heart left ventricle weight to right ventricle weight ratio control condition Hattori T, et al., Nutr Diabetes. 2011 Jan 31;1:e1. doi: 10.1038/nutd.2010.1. heart left ventricle mass male 126 days 7 4.74 null 0.12 0.32 post excision weight measurement 0.0 0 lv/rv 101898 2642
SS.ZUC-Leprfa-/-/Slc heart left atrium weight to tibia length ratio control condition Hattori T, et al., Nutr Diabetes. 2011 Jan 31;1:e1. doi: 10.1038/nutd.2010.1. heart left atrium mass male 126 days 7 2.55 mg/mm 0.14 0.37 post excision weight measurement 0.0 0 a/tl 101900 2642
SS.ZUC-Leprfa-/-/Slc ratio of survivors of metabolic syndrome to total study population during a period of time control condition Hattori T, et al., Nutr Diabetes. 2011 Jan 31;1:e1. doi: 10.1038/nutd.2010.1. total life span male 126 days 20 35.0 % necropsy 0.0 0 ratio of survivors of metabolic syndrome to total study population during a period of time (CMO:0003803) 101910 2642
SS.ZUC-Leprfa-/-/Slc serum total cholesterol level vehicle control condition (0.5 %) (for 28 days) Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4. blood cholesterol amount male 91 days 6 333.0 mg/dl 15.6 38.21 serum total cholesterol measurement test 0.0 0 101941 2644
SS.ZUC-Leprfa-/-/Slc serum insulin level vehicle control condition (0.5 %) (for 28 days) Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4. blood insulin amount male 91 days 6 0.0 mg/dl 0.0 0.0 serum insulin analysis 0.0 0 101959 2644
SS.ZUC-Leprfa-/-/Slc left ventricular end-diastolic blood pressure atorvastatin (20 mg/kg/d) (for 28 days) Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4. heart left ventricular blood pressure trait male 91 days 13 8.77 mmHg 1.87 6.74 vascular transducer tipped catheter 0.0 0 102024 2644
SS.ZUC-Leprfa-/-/Slc heart left ventricular end-diastolic blood pressure to heart left ventricular end-diastolic diameter ratio atorvastatin (6 mg/kg/d) (for 28 days) Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4. heart left ventricular blood pressure trait male 91 days 13 1.2 mmHg/mm 0.25 0.9 vascular transducer tipped catheter 0.0 0 102026 2644
SS.ZUC-Leprfa-/-/Slc blood total cholesterol level everolimus (0.83 mg/kg/d) (for 28 days) Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. blood cholesterol amount male 91 days 12 297.67 mg/dl 35.78 123.95 blood cholesterol analysis 0.0 0 101840 2641
SS.ZUC-Leprfa-/-/Slc blood low density lipoprotein cholesterol level everolimus (0.83 mg/kg/d) (for 28 days) Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. blood LDL cholesterol amount male 91 days 12 38.17 mg/dl 1.53 5.3 blood cholesterol analysis 0.0 0 101848 2641
SS.ZUC-Leprfa-/-/Slc epididymal fat pad weight to tibia length ratio control condition Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. epididymal fat pad mass male 91 days 7 3.17 g/cm 0.12 0.32 post excision weight measurement 0.0 0 ef/tl 101777 2641
SS.ZUC-Leprfa-/-/Slc heart left ventricle weight to tibia length ratio everolimus (0.83 mg/kg/d) (for 28 days) Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. heart left ventricle mass male 91 days 12 0.25 g/cm 0.0 0.01 post excision weight measurement 0.0 0 lv/tl 101762 2641